The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011

The prevalence of asthma in 2005 across the US, Japan, France, Germany, Spain, Italy and the UK was estimated at 53.2m people, corresponding to a prevalence rate of 7.7%. The highest prevalence rate for asthma in any country in 2005 was 12.0% in the UK. It is forecast that by 2011, the total prevalence of asthma across the seven major markets will be 58.8m sufferers or 8.0% of the population. COPD is only significantly prevalent in adults, a contrary situation to that of asthma, in which pediatric patients are estimated to represent some 35% of the total asthmatic patient population across the 7 major markets. 56.4m individuals are estimated to suffer from COPD across the seven major markets, although extremely low rates of diagnosis are thought to have resulted in a treated population of less than 10m individuals. Increasingly, COPD is becoming a major disease burden across the seven major markets, with a forecast patient population of 60.8m individuals by 2011, indicating high levels of future patient potential. Currently the treatment of asthma/COPD favors the use of beta-2 agonists and inhaled corticosteroids, with leukotriene antagonists and anticholinergics being positioned as additional therapies in either pediatric or last-line patients. With an estimated patient potential of 1.5bn in 2005, allergic rhinitis (AR) is associated with the largest disease burden of any major chronic respiratory disease by virtue of its high prevalence and its impacts on quality of life and productivity. It is believed that AR and asthma frequently co-exist and AR is a significant risk factor for asthma. Across the seven major markets, the prevalence of AR is forecast to increase to 1.8bn individuals in 2011, driven by the effect of raised levels of allergenic exposure, in both indoor and outdoor environments.

July 2006 PDF Pages 163
Table of Contents
Price: $2,875.00 / GBP1,897.50